EAN 2026 | What is currently known about broad rim lesions in multiple sclerosis?
Joost Smolders, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, gives an overview of what is currently known about broad rim lesions in multiple sclerosis. Dr Smolders highlights that patients with a more severe disease course have broad rim lesions on post-mortem tissue, but further research is needed. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think in our work thus far, we only scratched the surface of really understanding what the chronic-time lesions actually mean. I mean, what we currently know about it is that if we look to post-mortem tissue of Netherlands Brain Bank donors, that donors who experienced a very severe disease course during life, they more frequently have these broad rims of demyelination surrounding mixed active and inactive lesions while this is actually lacking in people with a very mild disease course and you know we only understand parts of the biology and we know we can at least identify correlates of these on PET imaging but this is all there is right now...
I think in our work thus far, we only scratched the surface of really understanding what the chronic-time lesions actually mean. I mean, what we currently know about it is that if we look to post-mortem tissue of Netherlands Brain Bank donors, that donors who experienced a very severe disease course during life, they more frequently have these broad rims of demyelination surrounding mixed active and inactive lesions while this is actually lacking in people with a very mild disease course and you know we only understand parts of the biology and we know we can at least identify correlates of these on PET imaging but this is all there is right now. So there’s really a need for us to further work on this, to understand what it means biologically, what kind of aspects of MS drive the development of these broad-time lesions, and more importantly, how can we image these in clinical cohorts to really also understand whether we can replicate these findings in independent cohorts and also really understand whether it helps us to capture the biology of MS more precisely.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
